Pharmacology Knowledge Graphs: Do We Need Chemical Structure for Drug Repurposing?

• URL: http://arxiv.org/abs/2603.01537v1
• Date: Mon, 02 Mar 2026 07:07:32 GMT
• Title: Pharmacology Knowledge Graphs: Do We Need Chemical Structure for Drug Repurposing?
• Authors: Youssef Abo-Dahab, Ruby Hernandez, Ismael Caleb Arechiga Duran,
• Abstract summary: We constructed a pharmacology knowledge graph from ChEMBL 36 comprising 5,348 entities including 3,127 drugs, 1,156 proteins, and 1,065 indications.<n>We benchmarked five knowledge graph embedding models and a standard graph neural network with 3.44 million parameters that incorporates drug chemical structure using a graph attention encoder and ESM-2 protein embeddings.<n>Removing the graph attention based drug structure encoder and retaining only topological embeddings combined with ESM-2 protein features improved drug protein PR-AUC from 0.5631 to 0.5785 while reducing VRAM usage from GB to 353 MB.
• Score: 0.0
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: The contributions of model complexity, data volume, and feature modalities to knowledge graph-based drug repurposing remain poorly quantified under rigorous temporal validation. We constructed a pharmacology knowledge graph from ChEMBL 36 comprising 5,348 entities including 3,127 drugs, 1,156 proteins, and 1,065 indications. A strict temporal split was enforced with training data up to 2022 and testing data from 2023 to 2025, together with biologically verified hard negatives mined from failed assays and clinical trials. We benchmarked five knowledge graph embedding models and a standard graph neural network with 3.44 million parameters that incorporates drug chemical structure using a graph attention encoder and ESM-2 protein embeddings. Scaling experiments ranging from 0.78 to 9.75 million parameters and from 25 to 100 percent of the data, together with feature ablation studies, were used to isolate the contributions of model capacity, graph density, and node feature modalities. Removing the graph attention based drug structure encoder and retaining only topological embeddings combined with ESM-2 protein features improved drug protein PR-AUC from 0.5631 to 0.5785 while reducing VRAM usage from 5.30 GB to 353 MB. Replacing the drug encoder with Morgan fingerprints further degraded performance, indicating that explicit chemical structure representations can be detrimental for predicting pharmacological network interactions. Increasing model size beyond 2.44 million parameters yielded diminishing returns, whereas increasing training data consistently improved performance. External validation confirmed 6 of the top 14 novel predictions as established therapeutic indications. These results show that drug pharmacological behavior can be accurately predicted using target-centric information and drug network topology alone, without requiring explicit chemical structure representations.

Related papers

• MMM: Quantum-Chemical Molecular Representation Learning for Combinatorial Drug Recommendation [5.017879531498458]
  Drug-drug interactions (DDI) between co-prescribed medications remain a significant challenge.<n>We propose Multimodal DDI Prediction with Molecular Electron Localization Function (ELF) Maps (MMM)<n>MMM combines ELF-derived features that encode global electronic properties with a bipartite graph encoder that models local substructure interactions.<n>These results demonstrate the potential complementary ELF-based 3D representations to enhance prediction accuracy and support safer drug prescribing in clinical practice.
  arXiv  Detail & Related papers  (2025-10-09T08:03:14Z)
• Drug Repurposing Using Deep Embedded Clustering and Graph Neural Networks [10.858347895657737]
  We propose a machine learning pipeline that uses unsupervised deep embedded clustering, combined with supervised graph neural network link prediction.<n>A total of 9,022 unique drugs were partitioned into 35 clusters with a mean silhouette score of 0.8550.<n>Graph neural networks achieved strong statistical performance, with a prediction accuracy of 0.901, receiver operating characteristic area under the curve of 0.960, and F1-Score of 0.901.
  arXiv  Detail & Related papers  (2025-09-15T01:04:37Z)
• Aligned Manifold Property and Topology Point Clouds for Learning Molecular Properties [55.2480439325792]
  This work introduces AMPTCR, a molecular surface representation that combines local quantum-derived scalar fields and custom topological descriptors within an aligned point cloud format.<n>For molecular weight, results confirm that AMPTCR encodes physically meaningful data, with a validation R2 of 0.87.<n>In the bacterial inhibition task, AMPTCR enables both classification and direct regression of E. coli inhibition values.
  arXiv  Detail & Related papers  (2025-07-22T04:35:50Z)
• GramSeq-DTA: A grammar-based drug-target affinity prediction approach fusing gene expression information [1.2289361708127877]
  We propose GramSeq-DTA, which integrates chemical perturbation information with the structural information of drugs and targets. Our approach outperforms the current state-of-the-art DTA prediction models when validated on widely used DTA datasets.
  arXiv  Detail & Related papers  (2024-11-03T03:17:09Z)
• Dumpling GNN: Hybrid GNN Enables Better ADC Payload Activity Prediction Based on Chemical Structure [53.76752789814785]
  DumplingGNN is a hybrid Graph Neural Network architecture specifically designed for predicting ADC payload activity based on chemical structure. We evaluate it on a comprehensive ADC payload dataset focusing on DNA Topoisomerase I inhibitors. It demonstrates exceptional accuracy (91.48%), sensitivity (95.08%), and specificity (97.54%) on our specialized ADC payload dataset.
  arXiv  Detail & Related papers  (2024-09-23T17:11:04Z)
• YZS-model: A Predictive Model for Organic Drug Solubility Based on Graph Convolutional Networks and Transformer-Attention [9.018408514318631]
  Traditional methods often miss complex molecular structures, leading to inaccuracies. We introduce the YZS-Model, a deep learning framework integrating Graph Convolutional Networks (GCN), Transformer architectures, and Long Short-Term Memory (LSTM) networks. YZS-Model achieved an $R2$ of 0.59 and an RMSE of 0.57, outperforming benchmark models.
  arXiv  Detail & Related papers  (2024-06-27T12:40:29Z)
• Regressor-free Molecule Generation to Support Drug Response Prediction [83.25894107956735]
  Conditional generation based on the target IC50 score can obtain a more effective sampling space. Regressor-free guidance combines a diffusion model's score estimation with a regression controller model's gradient based on number labels.
  arXiv  Detail & Related papers  (2024-05-23T13:22:17Z)
• Bi-level Contrastive Learning for Knowledge-Enhanced Molecule Representations [68.32093648671496]
  We introduce GODE, which accounts for the dual-level structure inherent in molecules.<n> Molecules possess an intrinsic graph structure and simultaneously function as nodes within a broader molecular knowledge graph.<n>By pre-training two GNNs on different graph structures, GODE effectively fuses molecular structures with their corresponding knowledge graph substructures.
  arXiv  Detail & Related papers  (2023-06-02T15:49:45Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• Improved Drug-target Interaction Prediction with Intermolecular Graph Transformer [98.8319016075089]
  We propose a novel approach to model intermolecular information with a three-way Transformer-based architecture. Intermolecular Graph Transformer (IGT) outperforms state-of-the-art approaches by 9.1% and 20.5% over the second best for binding activity and binding pose prediction respectively. IGT exhibits promising drug screening ability against SARS-CoV-2 by identifying 83.1% active drugs that have been validated by wet-lab experiments with near-native predicted binding poses.
  arXiv  Detail & Related papers  (2021-10-14T13:28:02Z)
• Relational graph convolutional networks for predicting blood-brain barrier penetration of drug molecules [12.041672273431994]
  The evaluation of the BBB penetrating ability of drug molecules is a critical step in brain drug development. We employ the relational graph convolutional network (RGCN) to handle the drug-protein relations as well as the features of each individual drug. The performance was already promising, demonstrating the significant role of the drug-protein/drug relations in the prediction of BBB permeability.
  arXiv  Detail & Related papers  (2021-07-04T15:56:02Z)
• Ensemble Transfer Learning for the Prediction of Anti-Cancer Drug Response [49.86828302591469]
  In this paper, we apply transfer learning to the prediction of anti-cancer drug response. We apply the classic transfer learning framework that trains a prediction model on the source dataset and refines it on the target dataset. The ensemble transfer learning pipeline is implemented using LightGBM and two deep neural network (DNN) models with different architectures.
  arXiv  Detail & Related papers  (2020-05-13T20:29:48Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.